Prolensa

Drug Overview

In the specialized field of ophthalmology, the success of a surgical procedure often depends as much on post-operative care as it does on the surgeon’s skill. Prolensa is a premier medication within the NSAID (Non-Steroidal Anti-Inflammatory Drug) class, specifically formulated to manage the eye’s natural healing response after surgery. Cataract surgery, while routine, involves the physical manipulation of ocular tissues, which inevitably triggers a chemical cascade leading to swelling and discomfort. Prolensa provides a TARGETED THERAPY to quiet this response, ensuring that patients recover with minimal pain and the best possible visual outcome.

This medication is a topical solution that allows for high concentrations of the active ingredient to reach the internal structures of the eye. Because it is highly potent, it offers the convenience of once-daily dosing, which significantly improves patient compliance during the critical recovery window.

• Generic Name: Bromfenac ophthalmic solution 0.07%
• US Brand Names: Prolensa
• Route of Administration: Topical Drops
• FDA Approval Status: Fully FDA-approved for the treatment of post-operative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery.

What Is It and How Does It Work? (Mechanism of Action)

Prolensa is a potent NSAID that functions by intercepting the body’s pain and inflammation signals at a molecular level. To understand how it works, we must look at the “arachidonic acid cascade,” a biological process that occurs whenever tissue is stressed or injured during surgery.

When the eye undergoes surgery, enzymes release arachidonic acid from cell membranes. This acid is then converted into prostaglandins by two specific enzymes: cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Prostaglandins are the primary chemical “messengers” responsible for causing the blood-aqueous barrier to break down. This breakdown leads to:

1. Vasodilation (widening of blood vessels).
2. Increased vascular permeability (leaky vessels).
3. The migration of white blood cells into the anterior chamber of the eye.
4. Direct stimulation of pain receptors.

The active ingredient in Prolensa, bromfenac, is a small molecule designed to penetrate the cornea rapidly. Once inside, it acts as a competitive inhibitor of both COX-1 and COX-2 enzymes. By physically blocking the active sites of these enzymes, bromfenac stops the production of prostaglandins before they can cause clinical symptoms. This molecular blockade reduces the “flare” (protein leakage) and “cells” (white blood cell accumulation) typically seen after cataract surgery. Physiologically, this keeps the internal environment of the eye calm, prevents the iris from becoming “sticky” or inflamed, and significantly lowers the patient’s perception of pain and grittiness.

FDA-Approved Clinical Indications

Primary Indication

The primary use of Prolensa is the treatment of post-operative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery. It is specifically designed to be used in the days following the removal of the clouded lens and the implantation of an artificial intraocular lens (IOL).

Other Approved & Off-Label Uses

While its FDA-approved label is focused on cataract surgery, eye specialists often utilize Prolensa in other scenarios to manage the ocular surface and retinal health:

• Prevention of Pseudophakic Macular Edema: Used off-label to prevent fluid buildup in the central retina (macula) following surgery, a condition known as Irvine-Gass Syndrome.
• Chronic Ocular Surface Disease: In some cases, it is used for short-term control of severe inflammation associated with chronic dry eye.
• Adjunct to Steroid Therapy: Often used alongside topical corticosteroids to provide a multi-modal approach to severe uveitis or chronic inflammation.

Primary Ophthalmology Indications

• Preserving Visual Acuity: By preventing protein and cell accumulation in the visual axis, the drug ensures light passes clearly to the retina during the healing phase.
• Stabilizing the Blood-Retinal Barrier: Effective COX inhibition prevents prostaglandins from traveling to the back of the eye, reducing the risk of vision-threatening retinal swelling.
• Managing Post-Surgical Ocular Pressure: By reducing internal inflammation, the drug helps prevent secondary spikes in intraocular pressure that can occur when the eye’s drainage system is “clogged” by inflammatory debris.

Dosage and Administration Protocols

To achieve optimal results, Prolensa must be started shortly before the surgical event. This “pre-loading” helps suppress the COX enzymes before the first incision is made.

Specific Instructions

1. Preparation: Always wash hands thoroughly before administration.
2. Timing: Treatment should begin 1 day prior to cataract surgery, continue on the day of surgery, and extend through the first 14 days of the post-operative period.
3. Technique: Pull down the lower eyelid to create a small pocket. Instill one drop without touching the dropper tip to the eye or eyelashes to maintain a sterile environment.
4. Punctal Occlusion: Gently press the inner corner of the eye (near the nose) for one minute after instilling the drop. This keeps the medicine on the eye surface and minimizes systemic absorption.
5. Multi-drop Protocol: If you are using other drops, such as antibiotics or steroids, wait at least 5 minutes between different drops to prevent washout.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Clinical data from 2020 through 2026 has reaffirmed the high efficacy of once-daily bromfenac 0.07%. In Phase 3 clinical trials, Prolensa demonstrated a statistically significant advantage over placebo in achieving a “clearing” of anterior chamber cells and flare.

Numerical data from recent post-market surveillance (2022-2024) indicates that:

• Approximately 80% to 85% of patients using Prolensa reported a “pain score of zero” by the first day after surgery.
• In studies using Optical Coherence Tomography (OCT), patients treated with this NSAID showed a mean change in Central Retinal Thickness (CRT) of less than 10 micrometers, compared to significantly higher thickening in control groups. This highlights the drug’s role in preventing macular edema.
• Visual outcomes remained stable, with treated patients maintaining a high Best Corrected Visual Acuity (BCVA), typically achieving 20/20 or 20/25 vision more rapidly as inflammatory debris cleared.

The drug is particularly efficacious in preventing vision loss by shielding the macula from the biological “storm” that occurs during phacoemulsification (the ultrasound process used to break up the cataract).

Safety Profile and Side Effects

There is currently NO BLACK BOX WARNING for Prolensa. It is generally well-tolerated when used for the recommended 14-day duration.

Common Side Effects (>10%)

• Transient stinging or burning upon instillation.
• Conjunctival hyperemia (mild redness of the white of the eye).
• Foreign body sensation (the feeling of something in the eye).

Serious Adverse Events

While rare, serious complications can occur, particularly in patients with pre-existing ocular surface disease:

• Corneal Melting: In high-risk patients (e.g., those with poorly controlled diabetes or rheumatoid arthritis), prolonged use of topical NSAIDs can lead to corneal thinning or perforation.
• Epithelial Breakdown: The medication can occasionally cause the top layer of the cornea to slough off, increasing the risk of infection.
• Hypersensitivity: Rare systemic allergic reactions, especially in those with known sensitivities to aspirin or other NSAIDs.

Management Strategies

To ensure safety, surgeons often utilize Preservative-Free artificial tears alongside Prolensa to protect the corneal surface. Patients are monitored via slit-lamp examinations for “floaters” or sudden pain, which could indicate a rare intraocular complication or corneal integrity issue.

Research Areas

Direct Clinical Connections: Current research in 2025 and 2026 is investigating the role of Prolensa in protecting the health of the Retinal Pigment Epithelium (RPE) and the neuroprotection of the optic nerve. By limiting the chronic low-grade inflammation that follows surgery, researchers believe they can better preserve the long-term health of retinal cells.

Generalization: Within the broader 2020-2026 research landscape, emphasis has shifted toward Novel Delivery Systems. Active clinical trials are exploring sustained-release intraocular implants and hydrogel inserts that would eliminate the need for daily drops. Furthermore, the development of Biosimilars and Preservative-Free formulations for multi-dose bottles is a major focus to reduce ocular surface toxicity.

Severe Disease & Surgical Integration: Research is evaluating the efficacy of bromfenac as an adjunct to complex vitrectomies or corneal transplants. In these high-stakes surgeries, preventing blindness depends on absolute control of the inflammatory response to prevent graft rejection or retinal scarring.

Disclaimer: These studies regarding sustained-release implants and RPE neuroprotection are currently in the preclinical or investigational phase and are not yet applicable to practical or professional clinical scenarios.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Visual Acuity (BCVA) and Tonometry (IOP measurement).
• Ocular Imaging: Optical Coherence Tomography (OCT) to document baseline Central Retinal Thickness and Fundus Photography.
• Screening: History of ocular surgeries, herpes simplex keratitis (as NSAIDs can trigger recurrence), and allergies to NSAIDs or preservatives like BAK.

Monitoring and Precautions

• Vigilance: Monitoring for “rebound” inflammation once the drops are discontinued.
• Lifestyle: Advise patients on the use of UV protection (sunglasses) and eyelid hygiene (lid scrubs) to prevent secondary irritation during the healing phase.
• Do’s and Don’ts:
  • Do use the drop at the same time every day to maintain a steady concentration.
  • Do wait 10 minutes before reinserting contact lenses (though lenses are usually restricted after surgery).
  • Don’t rub the eye under any circumstances, as this can damage the surgical incision or the cornea.
  • Don’t stop the drops early unless directed by your surgeon.

Legal Disclaimer

This information is for educational purposes only and is not intended as medical advice. Prolensa is a prescription medication that must be used under the direct supervision of a licensed ophthalmologist or healthcare professional. Always seek the advice of your physician regarding any questions about a medical condition or treatment plan. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide.